ADC Therapeutics (ADCT) Non-Current Assets (2019 - 2026)

ADC Therapeutics (ADCT) has reported Non-Current Assets for 8 consecutive years, with $14.7 million the latest figure, recorded in Q1 2026.

• Quarterly Non-Current Assets rose 1.22% year-over-year to $14.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $37.0 million (down 52.48% YoY) and the FY2025 annual result came in at $16.8 million, down 45.27% from the prior year.
• Non-Current Assets declined to $14.7 million in Q1 2026 per ADCT's latest filing, from $16.8 million in the prior quarter.
• Over the last five years, Non-Current Assets for ADCT reached as high as $96.0 million in Q2 2022 and fell as low as $2.6 million in Q3 2025.
• A 5-year average of $45.0 million and a median of $18.5 million in 2023 frame the typical range for Non-Current Assets.
• Annual changes were most pronounced in 2024 — Non-Current Assets surged 66.17% — and 2025, when it slumped 83.77%.
• Year by year, Non-Current Assets stood at $55.9 million in 2022, then tumbled by 66.91% to $18.5 million in 2023, then jumped by 66.17% to $30.7 million in 2024, then slumped by 45.27% to $16.8 million in 2025, then retreated by 12.41% to $14.7 million in 2026.
• According to Business Quant data, Non-Current Assets over the past three periods registered $14.7 million, $16.8 million, and $2.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.